MATWIN’s platform objectives
MATWIN (Maturation & Accelerating Translation With Industry) is the only French open-innovation platform specifically dedicated to oncology. MATWIN, a wholly owned subsidiary of Unicancer group (gathering all the French Comprehensive Cancer Centres) offers since 15 years several actions (expertise, accelerating program, events, etc.) aiming at accelerating the development of innovative projects dedicated to the fight against cancer.
15 years of projects supported by MATWIN (2009-2024)
For more than 15 years, MATWIN has supported more than 300 projects and led to the creation of more than 50 startups.
Download the booklet of testimonials from project leaders/partners produced for MATWIN’s 15th anniversary.
Research
Strenghten innovations’ transfer potential in partnership with the national ecosystem (canceropôles, TTOs, clusters …
Industry
Mutualize a sourcing platform of « shortlisted » early innovative projects
Patients
Contribute to accelerate treatments/ diagnostics outlooks
How to work with MATWIN ?
MATWIN in figures
supported projects
applicants for the MATWIN program
projects interviewed by the MATWIN board
start-up created
MEET2WIN participants
MEET2WIN : our annual partnering convention dedicated to open innovation in oncology
News
Brenus Pharma Initiates Clinical Trial for Its Candidate STC-1010
Brenus Pharma has announced the launch of an international phase I/IIa clinical trial evaluating STC-1010, a next-generation immunotherapy developed through [...]
One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling
One Biosciences, founded by Dr. Céline Vallot, Curie Institute and Home Biosciences in 2020, is an AI driven single cell [...]
Apmonia Therapeutics laureate from EIC accelerator program
Apmonia Therapeutics will receive €2.5 million in funding and €7 million in equity investment from the European Innovation Council (EIC) [...]